Anal Lett 54(14):22762292
doi: 10.3389/fphar.2025.1602976 Received 30 March 2025 Revised 13 November 2025 Accepted 14 November 2025 Published 19 December 2025 Volume 16 - 2025 Edited by Bernd Rosenkranz, Fundisa African Academy of Medicines Development, South Africa Reviewed by Kacper Nijakowski, Poznan University of Medical Sciences, Poland Miriam Njoki Karinja, Science for Africa Foundation, Kenya Updates Copyright 2025 Mazur, Ndokaj, Salerno, Vallone, Ardan, Bietolini, Carrouel, Wilk, Sarig, Ottolenghi and Bourgeois
IGF-1 LR3 Clinical Evidence Context Direct human evidence on IGF-1 LR3 There are no published human clinical trials of IGF-1 LR3 itself
GHK-Cu has the strongest mechanistic literature of the four
(2016) 19:E97E112
Nasal Spray TB-500 Nasal Spray Thymosin Beta-4 fragment nasal spray, 8mg total, 80 sprays at 100mcg per spray